Comorbidity in patients with cardiovascular disease who underwent a new coronavirus infection

• Andrey A. Obrezan
• Mariia V. Soloveva
• Lyubov V. Mikhailova
• Vadim V. Zaitsev
• Victoria E. Kon
• Alexey V. Panov

Abstract

According to Rosstat data for 2020, the total mortality in Russia against the background of the COVID‑19 pandemic increased by 19.2%. In parallel, there was also an increase in mortality from cardiovascular diseases (CVD) by 11.8%. Negative dynamics can be caused by a number of organizational and medical reasons. Among the first, it is worth noting a decrease in the volume of care provided to cardiological patients, due to the periodic conversion of hospitals for the treatment of patients with COVID‑19. Unpredictable stoppage and delays in the planned treatment of CVD can worsen the patient’s prognosis in a short time or lead to cardiological pathology decompensation. Voluntary patients refusals from hospitalization due to the unfavorable epidemiological situation and fear of intrahospital infection with COVID‑19 could also limit the availability of medical care. However, the increase in mortality from CVD is not only due to the difficulties of routing cardiological patients, but also the nature of the disease itself. A new coronavirus infection is often both the main cause of death and a serious concomitant disease that significantly affects the development of lethal complications with existing chronic pathology.

Keywords:chronic heart failure; new coronavirus infection; after-covid complications; comorbidity; rehabilitation

References

1. Inciardi R.M., Adamo M., Lupi L. et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020; 41 (19): 1821–9. DOI: https://doi.org/10.1093/eurheartj/ehaa388

2. Shlyakho E.V., Konradi A.O., Arutyunov G.P. et all. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020; 25 (3): 3801. DOI: https://doi.org/10.15829/1560-4071-2020-3-3801 (in Russian)

3. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75 (18): 2352–71. DOI: https://doi.org/10.1016/j.jacc.2020.03.031

4. Aghagoli G., Gallo M.B., Soliman L.B. et al. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J Card Surg. 2020; 35 (6): 1302–5. DOI: https://doi.org/10.1111/jocs.14538

5. Mehra M.R., Desai S.S., Ruschitzka F. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. S0140-6736(20)31180-6. DOI: https://doi.org/10.1016/S0140-6736(20)31180-6

6. Chen C., Zhou Y., Wang D. W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; 45 (3): 230–2. DOI: https://doi.org/10.1007/s00059-020-04909-z

7. Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med. 2020. Vol. 6. P. 1–4. DOI: https://doi.org/10.1007/s00134-020-06028-z

8. Tarasik E.S., Bulgak A.G., Zatoloka N.V., Koush E.V. The obstructive sleep apnea and cardiovascular diseases. Meditsinskie novosti [Medical news]. 2016; (6): 18–24. (in Russian)

9. Aliyeva A.M., Reznik E.V., Hasanova E.T., Zhbanov I.V., Nikitin I.G. Clinical value of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrenney meditsiny [The Russian Archives of Internal Medicine]. 2018; 8 (5): 333–45. DOI: https://doi.org/10.20514/2226-6704-2018-8-5-333-345

10. Malinnikova E.Yu. New coronaviral infection. Today’s look at the pandemic of the XXI century. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 (2): 18–32. DOI: https://doi.org/10.33029/2305-3496-2020-9-2-18-32 (in Russian)

11. Bubnova M.G., Persiyanova-Dubrova A.L., Lyamina N.P., Aronov D.M. Rehabilitation after new coronavirus infection (COVID-19): principles and approaches. CardioSomatics. 2020; 11 (4): 6–14. DOI: https://doi.org/10.26442/22217185.2020.4.200570

12. Polyclinic therapy. In I.I. Chukaeva, B.Ya. Bart ed. Moscow. KNORUS. 2017. 696 p. ISBN: 978-5-406-05915-9

13. Kozlov I.A., Tyurin I.N. Cardiovascular complications of COVID-19. Vestnik anesteziologii i reanimatolologii [Messenger of anesthesiology and resuscitation]. 2020; 17 (4): 14–22. DOI: https://doi.org/10.21292/2078-5658-2020-17-4-14-22 (in Russian)

14. Long B., Brady W. J., Koyfman A. et al. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020; 18: 1–4. DOI: https://doi.org/10.1016/j.Ajem.2020.04.048.

15. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75 (18): 2352–71. DOI: https://doi.org/10.1016/j.jacc.2020.03.031

16. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020; 25 (11): 4103. DOI: https://doi.org/10.15829/1560-4071-2020-4103 (in Russian)

17. Nazarov A.M., Borshchuk E.L. Risks of prolonged hospitalization in patients with myocardial infarction. Sovremennye problem nauki i obrazovaniya [Modern problems of science and education]. 2014; 4. (in Russian)

18. Bubnova M.G., Aronov D.M. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya [Pulmonology]. 2020; 30 (5): 688–99. DOI: https://doi.org/10.18093/0869-0189-2020-30-5-688-699 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)